Roche Venture Fund Research
Investment Thesis
Roche Venture Fund is the corporate venture capital arm of Roche, the Swiss pharmaceutical and diagnostics giant. Founded in 2002, it was set up as an independent entity to manage Roche's equity investments in biotech, diagnostics, and digital health companies. The fund's mandate is to "invest to develop commercially successful innovative life science companies," and it operates with a self-contained mandate for independent decision-making, separate from Roche's own R&D and business-development groups. It targets private companies with innovative medicines, diagnostics, and technologies that "share Roche's culture of innovation" and are willing to take risks on high-potential, high-reward science. The fund often co-invests alongside R&D collaborations with Roche or its Genentech subsidiary, giving portfolio companies a path to strategic partnership as well as capital.
Sector Focus
The fund invests across life sciences broadly, with three primary areas:
- Pharmaceuticals / biotech — small molecule and biologic drug discovery, gene and cell therapy, RNA/protein-splicing therapeutics
- Diagnostics — companies roughly 12-18 months from launch
- Digital health
Portfolio themes skew heavily toward oncology, rare/orphan diseases (CNS, neuromuscular, metabolic, kidney), immunology, and next-generation drug-delivery and protein-engineering platforms (e.g., intracellular delivery, bispecific antibodies, targeted protein degradation).
Stage Focus
Roche Venture Fund primarily targets Series A, though it is flexible around this. For therapeutics companies it prefers to invest at the preclinical stage; for diagnostics companies it prefers businesses roughly 12-18 months from launch. As an evergreen fund, it retains reserves for follow-on participation in later rounds of existing portfolio companies.
Check Size
Initial investments typically range from CHF 3-10 million (sources vary slightly, with some describing CHF 5-10 million), generally targeting around a 15-20% ownership stake, though the fund varies this "when appropriate."
Lead Tendency
Public reporting is mixed on whether Roche Venture Fund typically leads. It has participated as a co-investor in several rounds (e.g., COUR Pharmaceuticals' $105M Series A, co-led by Lumira Ventures and Alpha Wave Ventures; Mironid's Series A extension) rather than as the headline lead investor. Given the strategic/financial-hybrid nature of corporate venture capital and available evidence, lead tendency is best classified as unknown/both rather than a strong lead investor.
Recent Activity
The fund remains actively deploying as of 2026:
- April 2026: Invested in EpiBiologics (bispecific antibodies for targeted protein degradation)
- 2024: Co-invested in COUR Pharmaceuticals' $105M Series A (immune tolerance therapeutics)
- September 2023: Participated in Mironid's Series A extension (ADPKD small-molecule therapeutics)
- May 2023: Participated in DiogenX's EUR 27.5M Series A (diabetes biologics)
Portfolio Highlights
The fund has invested in more than 60 companies over its history, with a current active portfolio of roughly 30 companies across 10 countries. Notable current holdings include Freenome (blood-based early cancer detection), Sarepta Therapeutics (genetic medicines for neuromuscular/CNS disease), SpliceBio (protein-splicing genetic medicines, clinical stage), Entrada Therapeutics (intracellular delivery platform), Vivet Therapeutics (gene therapy for metabolic disease, clinical stage), Enliven Therapeutics (kinase inhibitors for cancer), and Minoryx (CNS orphan disease treatments).
Notable exits across the fund's history include 35 M&A acquisitions and 36 IPOs, among them 23andMe, Blueprint Medicines, FibroGen, and Halozyme Therapeutics.
Team
- Anja Harmeier — Head, Roche Venture Fund
- Monique Schiersing — Senior Investment Director
- Simon Greenwood — Senior Investment Director
- Bryan Faust — Investment Director
- Gabriella Zöch — Project Manager
Decision Process
The Roche Venture Fund team operates as a self-contained unit with an explicit "mandate for independent decision making on new and existing investments," distinguishing it from a strict corporate-committee model. Given its small, senior team structure (a Head plus a handful of Investment Directors), decisions are best characterized as a partnership-style process among senior investment staff rather than a large investment committee.
Founder Preferences
Roche Venture Fund favors scientific founding teams building on differentiated biology or platform technology — companies "willing to take risks on innovations with high potential reward" and whose culture aligns with Roche's own innovation focus. Many portfolio companies are spinouts or platform plays led by experienced life-science operators and academics rather than first-time generalist founders.
Geographic Focus
The fund describes itself as global, with dual headquarters in Basel, Switzerland and South San Francisco, California, giving it a natural bridge between European and US biotech ecosystems. Its ~30-company active portfolio spans roughly 10 countries across Europe, North America, and the Pacific region.
Fund Structure
Roche Venture Fund is structured as an evergreen fund (not a traditional fixed-life fund with a defined vintage), reported at approximately CHF 750 million, allowing continuous reinvestment and long-duration support for portfolio companies including follow-on rounds.